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a b s t r a c t
Mutations in the human ether-a-go-go-related gene (hERG) cause long-QT syndrome type 2 (LQT2). We
previously described a homozygous LQT2 nonsense mutation Q1070X in which the mutant mRNA is degraded
by nonsense-mediated mRNA decay (NMD) leading to a severe clinical phenotype. The degradation of the
Q1070X transcript precludes the expression of truncated but functional mutant channels. In the present
study, we tested the hypothesis that inhibition of NMD can restore functional expression of LQT2 mutations
that are targeted by NMD. We showed that inhibition of NMD by RNA interference-mediated knockdown of
UPF1 increased Q1070X mutant channel protein expression and hERG current amplitude. More importantly,
we found that speciﬁc inhibition of downstream intron splicing by antisense morpholino oligonucleotides
prevented NMD of the Q1070X mutant mRNA and restored the expression of functional Q1070X mutant
channels. The restoration of functional expression by antisense morpholino oligonucleotides was also
observed in LQT2 frameshift mutations. Our ﬁndings suggest that inhibition of NMD by antisense morpholino
oligonucleotides may be a potential therapeutic approach for some LQT2 patients carrying nonsense and
frameshift mutations.
© 2010 Elsevier Ltd. All rights reserved.

1. Introduction
Long-QT syndrome is a disease associated with delayed cardiac
repolarization and prolonged QT intervals on the electrocardiogram,
which can lead to ventricular arrhythmias and sudden death [1]. The
congenital long-QT syndrome type 2 (LQT2) is caused by mutations in
the human ether-a-go-go-related gene (hERG) [2]. hERG encodes the
pore-forming subunit of the rapidly activating delayed rectiﬁer K+
channel (IKr) in the heart [3–5]. Over 500 hERG mutations have been
identiﬁed in patients with LQT2 [6–11]. Approximately 30% of LQT2
mutations are nonsense or frameshift mutations that introduce
premature termination codons (PTCs). We have recently shown that
hERG nonsense mutations lead to the degradation of mutant mRNA
transcripts by nonsense-mediated mRNA decay (NMD) [12,13]. NMD
prevents the production of truncated and potentially harmful proteins
by eliminating abnormal mRNA transcripts carrying PTCs [14]. However,
the elimination of mutant mRNAs that would otherwise produce
partially or fully functional proteins may lead to a severe clinical
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phenotype [14]. Thus, interventions preventing the degradation of PTCcontaining transcripts may be therapeutically useful [15,16].
We recently reported a homozygous hERG nonsense mutation
Q1070X that causes profound QT prolongation and severe ventricular
arrhythmias [13]. We showed that hERG channels with the Q1070X
mutation trafﬁc normally to the plasma membrane and generate
hERG current when expressed from hERG cDNA. However, using a
minigene construct, we found that the Q1070X mutation causes a
marked decrease in mutant mRNA transcripts by the NMD pathway.
Thus, in homozygous Q1070X patients, most hERG mRNA transcripts
are degraded by NMD before they form functional channels leading to
a severe clinical phenotype [13,17]. Because the Q1070X mutant is
able to form functional hERG channels if the mutant mRNA transcripts
are not eliminated by NMD, inhibition of NMD might restore
functional expression of this truncated channel and therefore provide
a potential treatment for homozygous hERG Q1070X patients.
In the present study, we tested the hypothesis that inhibition of
NMD can restore functional expression of the hERG mutations
associated with long-QT syndrome. We report that inhibition of
NMD by RNA interference (RNAi)-mediated knockdown of UPF1
increased Q1070X mutant channel protein level and hERG current
amplitude. More importantly, we show that speciﬁc inhibition of
downstream intron splicing by antisense morpholino oligonucleotides (MO) prevented NMD of Q1070X mutant mRNA, leading to the
functional expression of Q1070X mutant channels. This strategy was

also used to restore the functional expression of two LQT2 frameshift
mutations. Our ﬁndings suggest that inhibition of NMD by antisense
MO may represent a novel therapeutic approach for some PTCcontaining mutations in LQT2 and other NMD-related diseases.

amino acids of HPH. The anti-HPH antibody was afﬁnity puriﬁed and
used at a 1:1000 dilution. The intensity of protein bands was
quantiﬁed using Scion Image software.
2.5. RNA interference

2. Materials and methods
2.1. Plasmid constructs and transfection
The hERG minigene composed of hERG cDNA exons 1–10 and
hERG genomic DNA from intron 10 to poly(A) site was constructed by
replacing hERG cDNA C-terminal fragment with an intron-containing
hERG genomic DNA fragment obtained from a human BAC clone
consisting of the entire hERG gene (RP11-166D23). The minigene was
subcloned into a modiﬁed pcDNA5 vector in which the BGH poly(A)
signal was deleted. Thus, the native poly(A) signal of hERG gene is
used for the formation of the poly(A) tail of hERG mRNA. The Q1070X,
R1005fs + 50X and Q1010fs + 45X mutations were generated by sitedirected mutagenesis using the pAlter in vitro mutagenesis system
(Promega, Madison, WI). Flp-In HEK293 cells (Invitrogen, Carlsbad,
CA) were stably transfected with pcDNA5 hERG cDNA or minigene
constructs and selected with 100 μg/ml hygromycin B. Flp-In HEK293
cells, which contain a single integrated Flp recombination target site,
allow stable integration of a single copy of the cDNA or minigene
construct at a speciﬁc genomic site and, subsequently, similar
expression in all cell clones.

UPF1 shRNA was used to inhibit expression of UPF1 as described
previously [12]. The shRNA targeted the coding sequence of hUPF1
(5′-GAGAATCGCCTACTTCACT-3′). HEK293 cells stably expressing WT
or Q1070X minigenes were stably transfected with plasmids containing
the UPF1 or scramble shRNA. The knockdown of the UPF1 protein was
analyzed by immunoblot as previously described [12].
2.6. Patch clamp recordings
Membrane currents were recorded in whole cell conﬁguration
using suction pipettes as previously described [18]. hERG current was
activated by depolarizing steps between −70 and 60 mV from a
holding potential of −80 mV. The hERG tail current was recorded
following repolarization to −50 mV. All patch clamp experiments
were performed at room temperature (22–23 °C). The patch clamp
data are presented as mean ± SEM and analyzed by Student's t-test.
p b 0.05 is considered statistically signiﬁcant.
3. Results
3.1. Effect of NMD on the Q1070X mutation in minigene experiments

2.2. Morpholino oligonucleotide treatment
MOs were synthesized by Gene Tools (Philomath, OR). The
antisense MO was designed to target the 5′ splice site of intron 14,
5′-aagcagggctggagcttacCTGAGA-3′ (upper case indicates exonic
sequences and lower case indicates intronic sequences). An invert
MO with the same sequence but in a reverse orientation was used as a
control. The Endo-Porter delivery system (Gene Tools) was used to
deliver the MOs into the cells.
2.3. RNase protection assay
RNA isolation and RPA were performed as previously described
[12]. Brieﬂy, antisense RNA riboprobes were transcribed in vitro in the
presence of biotin-14-CTP. The probe designed to detect the mRNA
levels of the hERG minigene contained 277 nt spanning the region of
exons 12 and 13. The total length of the probe was 409 nt and
contained sequences from the pCRII vector at both ends. The probe
designed to detect intron 14 splicing events contained 222 nt
spanning the region of exon 14 and intron 14. The total length of
the probe was 336 nt and contained sequences from the pCRII vector
at both ends. The probe for the hygromycin B resistance gene
contained 158 nt of the gene and 70 nt from the pGEM vector. Yeast
RNA was used as a control for the complete digestion of the probes by
RNase. The relative intensity of each band was quantiﬁed using Scion
Image software (Scion Corp., Frederick, MD).
2.4. Immunoblot analysis
Immunoblot analysis was performed as previously described [18].
The cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and then electrophoretically transferred onto nitrocellulose
membranes. The membranes were probed with an anti-hERG
antibody against the N terminus of hERG protein (Santa Cruz
Biotechnology Inc., Santa Cruz, CA). The expression level of hygromycin B phosphotransferase (HPH) encoded by the hygromycin B
resistance gene in pcDNA5 vector was used as a loading control [19].
The polyclonal anti-HPH antibody was custom generated by Genscript
(Piscataway, NJ) using a peptide antigen corresponding to the last 14

We previously reported that the Q1070X mutation was able to
form functional hERG channels when expressed from hERG cDNA
[13]. However, the Q1070X mutation led to a marked decrease in
mutant mRNA transcripts by the NMD pathway in the context of a
minigene system. The minigene construct used in the previous study
contained only the hERG genomic sequence from exon 12 to exon 15,
which precluded analyses of hERG protein and channel function. In
order to study the effect of NMD on the Q1070X mutation at protein
and functional levels, we constructed a minigene that contained
hERG cDNA from exon 1 to exon 10 and hERG genomic DNA from
intron 10 to the poly(A) site (Fig. 1A). When expressed in HEK293
cells, this minigene was properly spliced to produce the full-length
hERG protein. As shown in Fig. 1B, the wild-type (WT) minigene
expressed two protein bands at 155 and 135 kDa, consistent with the
sizes of the hERG protein expressed from the hERG cDNA construct.
The 135-kDa band represents the core-glycosylated immature form
of the channel protein located in the ER, and the 155-kDa band
represents the complex-glycosylated mature form of the channel
protein located in the plasma membrane [20]. The Q1070X minigene
generated two protein bands at 125 and 145 kDa, reﬂecting the
deletion of 90 amino acids due to the premature termination codon.
However, the level of the two protein bands in the Q1070X mutant
minigene was markedly decreased compared to that of the WT
minigene. This is in contrast to the cDNA experiments in which the
protein expression levels of WT and Q1070X were comparable
(Fig. 1B). To determine whether the decrease in the protein
expression level of the Q1070X mutation is due to the degradation
of mutant mRNA by NMD, we carried out RNase protection assay
(RPA) analysis using a probe spanning a region of exon 12 and exon
13. The mRNA level of the Q1070X minigene was signiﬁcantly lower
than that of the WT minigene (Fig. 1C). Because degradation of
mRNA by NMD is dependent on protein synthesis, we examined
whether inhibition of protein synthesis by cycloheximide (CHX)
abrogates NMD of the mutant mRNA. Treatment with CHX had no
effect on the level of WT mRNA but signiﬁcantly increased the level
of Q1070X mutant mRNA, suggesting that the Q1070X mutant mRNA
is degraded by NMD. Functional analysis of hERG channels showed
that the degradation of the Q1070X mutant mRNA by NMD resulted

Fig. 1. Analysis of the Q1070X mutation in the context of the hERG minigene. (A) Diagram of the hERG minigene structure. The positions of WT termination codon (TER) and the
Q1070X mutation-induced PTC are indicated. (B) Immunoblot analysis of WT hERG and Q1070X cDNAs and minigenes. Cell lysates were subjected to SDS-PAGE and probed with
anti-hERG and the anti-HPH antibodies. The level of HPH served as a loading control. The level of protein bands was quantiﬁed, normalized to HPH, and shown as percentage of WT
minigene control (mean ± SEM, n = 3). (C) Analysis of mRNA in the hERG minigene by RPA. Cells expressing WT and Q1070X minigenes were treated (+) or not treated (−) with
100 μg/ml of CHX for 3 h before RNA isolation. The level of hygromycin B resistance gene transcripts (Hygro) served as a loading control. RPA signals were quantiﬁed, normalized to
hygromycin B resistance gene, and shown as percentage of WT control (n = 3). (D) Patch clamp recordings of hERG current in WT and Q1070X minigenes stably expressed in Flp-In
HEK293 cells.

in a signiﬁcant decrease in hERG current (Fig. 1D). The maximum tail
current amplitudes for WT and Q1070X minigenes were 22.5 ± 1.7
pA/pF (n=13) and 2.6 ± 0.5 pA/pF (n = 11, p b 0.05), respectively.
These experiments demonstrate that the full-length hERG minigene
is an ideal system to study NMD effects at the mRNA, protein, and
functional levels.

3.2. Effect of RNAi knockdown of UPF1 on expression of the
Q1070X mutation
Since the Q1070X mutation is able to form functional hERG
channels when the cDNA construct is used, we hypothesized that
inhibition of NMD can restore functional expression of the Q1070X

Fig. 2. Suppression of NMD of Q1070X by RNAi knockdown of UPF1. Cells stably expressing the WT and Q1070X minigenes were transfected with UPF1 or scramble shRNA plasmids.
(A) Immunoblot analysis of UPF1 protein. (B) RPA analysis of the effect of UPF1 knockdown on the level of mRNA. RPA signals were quantiﬁed, normalized to hygromycin B
resistance gene, and shown as percentage of WT control (n = 3). (C) Immunoblot analysis of the effect of UPF1 RNAi. Protein bands were quantiﬁed, normalized to HPH, and shown
as percentage of WT minigene control (n = 3). (D) patch clamp recordings.

Fig. 3. Inhibition of intron 14 splicing by antisense MO prevents NMD degradation of the Q1070X mutant mRNA. Cells stably expressing the WT and Q1070X minigenes were treated
with 4 μM invert or antisense MO for 48 h. (A) Diagram of the hERG minigene structure and the sequences of antisense MO. (B) RPA analysis of the effect of antisense MO on the level
of mRNA. RPA signals were quantiﬁed, normalized to hygromycin B resistance gene, and shown as percentage of WT control (n = 3). (C) Diagram showing the RPA probe and RNase
protected fragments corresponding to spliced and unspliced fragments from intron 14. (D) RPA analysis of the effect of antisense MO on intron 14 splicing.

mutation in the context of the minigene. Although the level of mutant
hERG mRNA increases as NMD is inhibited in the presence of CHX, the
inhibitory effects of CHX on protein synthesis preclude functional
studies of hERG channels. We therefore used the RNAi method to
knockdown UPF1, a key effector of the NMD pathway. In these
experiments, HEK293 cells stably expressing WT and Q1070X
minigenes were transfected with UPF1 or scramble short hairpin
RNA (shRNA) plasmids. UPF1 knockdown in the transfected cells was
conﬁrmed by immunoblot analysis using an anti-UPF1 antibody
(Fig. 2A). RPA analysis showed that the level of Q1070X mutant mRNA
was signiﬁcantly increased in UPF1-shRNA-transfected cells (Fig. 2B).
The knockdown of UPF1 also resulted in an increase in the level of the
Q1070X mutant protein. As shown in Fig. 2C, the protein level of
Q1070X was increased more than ﬁvefold in UPF1-shRNA-transfected
cells compared to scramble shRNA-transfected cells. Patch clamp
analysis revealed that UPF1 knockdown signiﬁcantly increased hERG
current amplitude of the Q1070X mutant (Fig. 2D). The maximum tail
current amplitudes for scramble shRNA and UPF1-shRNA were 1.9 ±
0.4 pA/pF (n = 8) and 10.8 ± 2.8 pA/pF (n = 9, p b 0.05), respectively.
These ﬁndings indicate that inhibition of NMD by UPF1 knockdown
upregulates the level of the Q1070X mutant protein leading to
functional expression of the Q1070X mutant channel.
3.3. Inhibition of NMD by antisense MO upregulates Q1070X
mutant mRNA
The above ﬁndings suggest that inhibition of NMD by UPF1
knockdown might provide a therapeutic strategy for patients carrying
the Q1070X mutation. However, downregulation of NMD components
potentially has adverse consequences as cellular clearance of PTCcontaining mRNAs by NMD is a critical house-keeping function [21]. It
is important to develop an approach that can speciﬁcally inhibit NMD
of the Q1070X mutant mRNA transcripts. Because the downstream
intron splicing plays an important role in the degradation of PTCcontaining mRNAs by NMD [22], we reasoned that inhibition of
downstream intron splicing by antisense MO might prevent NMD of
the Q1070X mutant mRNA and lead to the functional rescue of the
truncated mutant channels. MOs are nonionic DNA analogs that can
form RNA-morpholino hybrids to alter pre-mRNA splicing events by
blocking the access of splicing factors to splice sites. The Q1070X
mutation is located in exon 14 of the hERG gene with only one
downstream intron (intron 14). We designed an antisense MO
targeting the 5′ splice site of intron 14 to inhibit the splicing of intron

14 (Fig. 3A). In these experiments, HEK293 cells stably expressing WT
or Q1070X minigene were treated with antisense or invert MO for
48 h. As shown in Fig. 3B, treatment with antisense MO resulted in a
signiﬁcant increase in the level of the Q1070X mutant mRNA
transcripts compared to the control MO. To conﬁrm the inhibition of
intron 14 splicing by antisense MO, we carried out RPA analysis using
a probe spanning the region from exon 14 to intron 14. This probe
generates a protected fragment of 222 nt if the intron 14 is unspliced
and a 122-nt fragment if the intron 14 is spliced (Fig. 3C). Treatment
with the antisense MO resulted in an efﬁcient block of intron 14
splicing leading to a signiﬁcant increase in the unspliced form
(Fig. 3D). These results suggest that inhibition of intron 14 splicing
by antisense MO can prevent NMD of the Q1070X mutant mRNA
transcripts.
3.4. Increase of hERG mutant proteins in antisense MO treated cells
To determine whether inhibition of NMD by antisense MO also
results in the restoration of the Q1070X mutant at the protein level,
we analyzed hERG protein expression by immunoblot. HEK293 cells
stably expressing WT or Q1070X minigene were treated with
antisense or invert MO for 48 h. Treatment with antisense MO
signiﬁcantly increased the level of the Q1070X mutant protein
compared with the control invert MO (Fig. 4A). Because the Q1070X
mutation introduces a stop codon in exon 14, which is upstream of the
exon 14–intron 14 junction, intron 14 retention did not result in any
changes in the protein size of the Q1070X mutant. In HEK293 cells
expressing WT hERG, the antisense MO treatment allowed the read
through of protein synthesis into intron 14 up to a termination codon
within intron 14. This resulted in the replacement of the last 47 amino
acids of hERG protein by 77 amino acids encoded by the intron 14
sequence. The replacement caused a small increase in molecular mass
of WT hERG protein (~ 3 kDa), which did not cause a signiﬁcant shift of
protein bands on immunoblot analysis. In addition, the level of WT
hERG protein was not signiﬁcantly changed. The effect of antisense
MO on the level of the Q1070X protein showed concentration and
time dependence. The level of mutant protein was increased with
2 μM antisense MO and reached a maximum at 6 μM antisense MO
(Fig. 4B). The increase of the mutant protein level was observed by
24 h and reached a maximum by 72 h after treatment with antisense
MO (Fig. 4C).
To test whether antisense MO treatment can restore protein
expression of hERG frameshift mutations, we analyzed two LQT2

Fig. 5. Restoration of R1005fs + 50X and Q1010fs + 45X mutant protein expression by
antisense MO. Cells expressing the R1005fs + 50X and Q1010fs + 45X minigenes were
treated with 4 μM invert (Con) or antisense MO for 48 h. Cells expressing the WT
minigenes treated with invert MO were used as control. Cell lysates were subjected to
SDS-PAGE and immunoblotted with anti-hERG and anti-HPH antibodies. Signals were
quantiﬁed, normalized to HPH, and shown as percentage of WT control (n = 3).

Fig. 4. Restoration of Q1070X mutant protein expression by antisense MO.
(A) Immunoblot analysis of the effect of antisense MO on the level of hERG protein.
Cells expressing the WT and Q1070X minigenes were treated with 4 μM invert (Con) or
antisense MO for 48 h. Cell lysates were subjected to SDS-PAGE and immunoblotted
with anti-hERG and anti-HPH antibodies. Signals were quantiﬁed, normalized to HPH,
and shown as percentage of WT control (n = 3). (B) Concentration dependence of the
effect of antisense MO. Cells expressing Q1070X minigene were treated with antisense
MO at indicated concentrations for 48 h. Signals were quantiﬁed, normalized to HPH,
and shown as fold changes (0 concentration = 1, n = 3). (C) Time course of the effect of
antisense MO. Cells expressing Q1070X minigene were treated with 4 μM for
indicated times. Signals were quantiﬁed, normalized to HPH, and shown as fold
changes (0 time = 1, n = 3).

mutations R1005fs + 50X and Q1010fs + 45X by immunoblot. Both
R1005fs + 50X and Q1010fs + 45X are located in exon 13 and
introduce a PTC in exon 14 at amino acid 1056 [7,10]. HEK293 cells
stably expressing the R1005fs + 50X or Q1010fs + 45X minigene were
treated with antisense or invert MO for 48 h. Treatment with
antisense MO signiﬁcantly increased the levels of R1005fs + 50X
and Q1010fs + 45X mutant proteins (Fig. 5). These results suggest
that the antisense approach is able to restore the expression of
truncated proteins generated from LQT2 nonsense and frameshift
mutations.
3.5. Functional rescue of LQT2 mutant channels by antisense MO
To study functional rescue of the LQT2 mutant channels, we
performed patch clamp recordings of hERG current from antisense
MO-treated cells. Cells stably expressing WT and LQT2 mutants were
treated with 4 μM antisense MO for 48 h. For WT hERG minigene, the
current was not affected by the antisense MO treatment (Fig. 6A, B).
The maximum tail current amplitudes for WT hERG in the presence of
invert and antisense MO were 24.8 ± 2.9 pA/pF (n = 8) and 23.5 ± 2.5
pA/pF (n = 8, p ≥ 0.05), respectively. This suggests that the replacement of the last 47 amino acids of hERG protein with 77 amino acids
encoded by the intron 14 sequence does not have signiﬁcant effect on
WT hERG channel function. For the Q1070X and R1005fs + 50X

mutant minigenes, the hERG current was signiﬁcantly increased by
the antisense MO treatment (Fig. 6C, D, E, F). The maximum tail
current amplitudes for the Q1070X mutant treated with invert and
antisense MO were 2.4 ± 0.3 pA/pF (n = 8) and 19.2 ± 3.3 pA/pF
(n = 9, p b 0.05), respectively. The maximum tail current amplitudes
for the R1005fs + 50X mutant treated with invert and antisense MO
were 2.0 + 0.2 pA/pF (n = 6) and 17.7 ± 1.8 pA/pF (n = 7, p ≤ 0.05),
respectively. Antisense MO also increased the current amplitude of
the Q1010fs + 45X mutant (data not shown). To determine the I–V
relationship of WT and mutant channels, the peak tail current
amplitudes measured at −50 mV were plotted against preceding
test voltages in the presence of invert and antisense MO (Fig. 6G). The
voltage dependence of hERG channel activation was determined by
ﬁtting the normalized tail currents with a Boltzmann function. The
half maximal activation voltages (V1/2) and slope factor (k) for WT
hERG, Q1070X, and R1005fs + 50X were shown in Supplemental
Table S1. These patch clamp experiments demonstrate that inhibition
of NMD by antisense MO can rescue functional expression of the LQT2
nonsense and frameshift mutations.
4. Discussion
NMD is an evolutionarily conserved mRNA surveillance pathway
that detects and eliminates PTC-containing mRNA transcripts, thereby
preventing the synthesis of truncated and potentially harmful
proteins [23,24]. NMD as a modiﬁer of phenotypic severity has been
reported in many human diseases [14,15,25]. In most cases, NMD is
beneﬁcial, preventing the production of C-terminally truncated
proteins that often have dominant-negative effects. However, NMD
could be detrimental if it prevents the production of truncated
proteins that are fully or partially functional [26]. This appears to
apply to the hERG Q1070X mutation in which the degradation of
mutant mRNA by NMD precludes the formation of functional,
truncated channels and causes profound QT prolongation and severe
ventricular arrhythmias in homozygous subjects [13,17]. In the
present study, we show that speciﬁc inhibition of downstream intron
splicing by antisense MO effectively suppresses NMD of hERG
transcripts containing LQT2 mutations Q1070X, R1005fs + 50X, and
Q1010fs + 45X, leading to the restoration of mutant protein expression and rescue of hERG channel current. The functional rescue of
hERG mutant channels by antisense MO is efﬁcient, restoring up to
about 80% of the WT current level. Our ﬁndings demonstrate the
feasibility of targeting downstream intron splicing by antisense MO to
inhibit NMD as a means to rescue functional expression of mutant
hERG channels in LQT2.
Our results indicate that downstream intron splicing is required
for efﬁcient degradation of hERG transcripts containing PTCs by the
NMD pathway. Pre-mRNA splicing results in deposition of a protein

Fig. 6. Functional rescue of hERG current by antisense MO. (A–F) Representative currents recorded from Flp-In HEK293 cells stably expressing WT, Q1070X, and R1005fs + 50X
minigenes. Cells were treated with 4 μM invert (control) or antisense MO (AMO) for 48 h. (G) I–V plot of hERG tail current amplitude measured at −50 mV following test voltages
from −70 to 60 mV for WT hERG, Q1070X, and R1005fs + 50X cells in the presence of invert or antisense MO.

complex known as the exon junction complex (EJC) 20–24 nt
upstream of the splice junction [27,28]. According to the proposed
rule for NMD in mammalian cells, termination codons located N50–55
nt upstream of the 3′ most exon–exon junction elicit NMD [29]. The
EJC is usually displaced by ribosomes during the pioneer round of
translation. If translation terminates at a termination codon that is
located 50–55 nt upstream of an exon–exon junction, the presence of
a downstream EJC serves as a binding platform for NMD factors and
triggers NMD. Recently, it has been shown that some PTC-containing
mRNAs undergo NMD in the absence of a downstream EJC. These
experimental data support an NMD model in which the competitive
interaction between UPF1 and Poly(A) binding protein with the
ribosome-bound releasing factors is the key determinant for NMD
initiation [30]. Although the EJC is not required for NMD initiation in
this model, it may act as an enhancer for NMD [30]. Thus, in both
proposed models, EJCs play an important role in mammalian NMD.
The LQT2 mutations examined in this study introduce PTCs in exon 14
and are located N50–55 nt upstream of the last exon–exon junction.

Inhibiting splicing of the last intron precludes EJC deposition
downstream of these PTCs and prevents NMD of the mutant
mRNAs. Nonsense and frameshift mutations that introduce PTCs
upstream of exon 14 may require the inhibition of splicing of
additional introns to prevent degradation by NMD. Over 20 LQT2
nonsense and frameshift mutations introduce PTCs within exon 14,
and these mutant transcripts are potential candidates for rescue by
the antisense approach.
Several pharmacological approaches have been used to rescue
expression of mutant mRNAs that are targeted by the NMD pathway
[24,25]. For example, aminoglycoside antibiotics have been used to
suppress recognition of stop codons, leading to the synthesis of fulllength proteins from PTC-containing transcripts. This approach has
been tested for PTC mutations in several diseases including cystic
ﬁbrosis, Duchenne muscular dystrophy, and LQT2 [15,31–33].
Aminoglycoside antibiotics have been shown to increase hERG
current of LQT2 nonsense mutations R1014X and W927X [33]. The
major limitations of aminoglycoside antibiotic treatment are its low

efﬁciency and toxic side effects [32]. Recently, a small molecule PTC
124 has been shown to induce read through of PTCs and has less effect
on normal termination codons [32]. Another approach to restore the
expression of PTC-containing mRNA is the use of RNAi to knockdown
NMD factors. Inhibition of NMD by RNAi knockdown of UPF1 and
SMG-1 has been shown to restore the expression of mutant collagen
VI α2 protein in Ullrich disease [16]. Our results also show that
inhibition of NMD by RNAi-mediated knockdown of UPF1 results in
the functional rescue of Q1070X mutant channels. It has been
suggested that inhibition of the key factors involved in the NMD
pathway may represent a potential therapeutic strategy for some
genetic diseases exacerbated by NMD [16]. However, many physiological transcripts are subject to NMD regulation, and systematically
inhibiting NMD will likely result in undesirable side effects. Our
present ﬁndings demonstrate that targeting downstream intron
splicing by antisense MO offers an effective approach to speciﬁcally
prevent NMD of PTC-containing mRNA transcripts without inhibiting
the normal NMD pathway.
The antisense approach has been used to modulate mRNA splicing
in a variety of disease models such as thalassemia, cystic ﬁbrosis,
Duchenne muscular dystrophy [21,34,35]. The primary applications of
the antisense approach in these disease models are to restore normal
splicing by blocking cryptic splice sites and to rescue the normal
reading frame by skipping of exons that contain PTC mutations. In a
mouse model of Duchenne muscular dystrophy, antisense oligonucleotide-mediated exon skipping has been shown to efﬁciently
restore expression of functional dystrophin in skeletal and cardiac
muscles by systemic delivery of peptide-conjugated MO [36,37]. To
our knowledge, our present work is the ﬁrst reported use of antisense
MO to inhibit NMD of PTC-containing mRNA by blocking downstream
intron splicing. Since the antisense approach can speciﬁcally inhibit
NMD of targeted mRNAs without interfering with factors that are
necessary for normal NMD functions, it may represent a novel
therapeutic approach for some PTC mutations in LQT2 and other
NMD-related diseases.
Supplementary materials related to this article can be found online
at doi:10.1016/j.yjmcc.2010.10.022.
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